GE HealthCare Technologies Inc. (GEHC) stock surged 5.04% in intraday trading on Friday, driven by a combination of positive news and strong financial performance. The medical technology company is reportedly among the potential buyers evaluating HistoSonics, a Johnson & Johnson-backed firm specializing in sonic beam therapy for liver tumors. According to the Financial Times, HistoSonics is exploring a sale at a valuation of over $2.5 billion, with final bids expected in the coming weeks.

Adding to investor optimism, GE HealthCare announced plans to expand its radiation oncology portfolio at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2025 Congress. The company intends to incorporate Spectronic Medical AB's software offering, which enables MR-only radiotherapy workflows. GE HealthCare also introduced the AI-enabled MR Contour DL™, which received U.S. FDA 510(k) clearance for organs at risk (OAR) segmentation in radiation therapy planning. These innovations aim to improve clinical workflows and enhance patient care in oncology.

The stock's upward movement was further supported by GE HealthCare's impressive quarterly results. The company beat forecasts with revenue of $4.8 billion, 2.6% above estimates, and statutory earnings per share of $1.23, surpassing expectations by 38%. Despite a slight downward revision in earnings forecasts by analysts, the strong performance and potential for future growth through strategic acquisitions and product innovations have bolstered investor confidence in GE HealthCare's prospects.